Network meta-analysis reveals that efruxifermin shows greater efficacy and safety for metabolic dysfunction-associated steatohepatitis.
Efruxifermin demonstrated a slightly greater effect on MRI-PDFF and AST, along with more favourable safety outcomes.
No takes yet. Share an insight, caveat, or question.
Jaber et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: